![Brian Culley](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Brian Culley
Chief Executive Officer at LINEAGE CELL THERAPEUTICS, INC.
Net worth: 154 842 $ as of 30/05/2024
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Michael Mulroy | M | 58 | 10 years | |
Don Bailey | M | 78 | 8 years | |
George Samuel | M | 43 | 3 years | |
Neal Bradsher | M | 58 | 15 years | |
Angus Russell | M | 68 | 10 years | |
Anula Kusum Jayasuriya | M | 67 | 3 years | |
Deborah Andrews | F | 66 | 10 years | |
Dipti Amin | M | 60 | 3 years | |
Derek Kelaita | M | - | 5 years | |
Jill Howe | F | 48 | 2 years | |
Munish Mehra | M | - | - | |
Timothy Duane | M | - |
University of California, Berkeley
| 25 years |
Frank Lanza | M | 62 | 8 years | |
Gary Hogge | M | 56 | 6 years | |
Daniel M. Kammen | M | 62 |
University of California, Berkeley
| 25 years |
Michael Franklin | M | - |
University of California, Berkeley
| 25 years |
Ioana C. Hone | F | - | - | |
Ronald Kurtz | M | 61 |
University of California, Berkeley
| 24 years |
Jennifer Bahr-Davidson | M | - | 14 years |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Patrick Keran | M | 52 |
Mast Therapeutics, Inc.
![]() Mast Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Mast Therapeutics, Inc. is a biopharmaceutical company, which engages in developing novel therapies for serious or life-threatening diseases with significant unmet needs. It leveraging Molecular Adhesion and Sealant Technology, platform, derived from over two decades of clinical, nonclinical, and manufacturing experience with purified and non-purified poloxamers to develop vepoloxamer, which also known as MST-188. The company was founded by Warren C. Lau in December 1995 and is headquartered in San Diego, CA. | 9 years |
Brandi Roberts | F | 50 |
Mast Therapeutics, Inc.
![]() Mast Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Mast Therapeutics, Inc. is a biopharmaceutical company, which engages in developing novel therapies for serious or life-threatening diseases with significant unmet needs. It leveraging Molecular Adhesion and Sealant Technology, platform, derived from over two decades of clinical, nonclinical, and manufacturing experience with purified and non-purified poloxamers to develop vepoloxamer, which also known as MST-188. The company was founded by Warren C. Lau in December 1995 and is headquartered in San Diego, CA. | 9 years |
Alfred Kingsley | M | 81 | 15 years | |
Evan Levine | M | 59 |
Mast Therapeutics, Inc.
![]() Mast Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Mast Therapeutics, Inc. is a biopharmaceutical company, which engages in developing novel therapies for serious or life-threatening diseases with significant unmet needs. It leveraging Molecular Adhesion and Sealant Technology, platform, derived from over two decades of clinical, nonclinical, and manufacturing experience with purified and non-purified poloxamers to develop vepoloxamer, which also known as MST-188. The company was founded by Warren C. Lau in December 1995 and is headquartered in San Diego, CA. | 6 years |
Adi Mohanty | M | 57 | 4 years | |
Stephana Patton | M | 54 | 2 years | |
Judith Segall | F | 70 | 29 years | |
Steve Cartt | M | 61 | 3 years | |
S Chu Schubert | M | 51 |
University of California, Berkeley
| 8 years |
Shana C. Hood | F | - |
Mast Therapeutics, Inc.
![]() Mast Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Mast Therapeutics, Inc. is a biopharmaceutical company, which engages in developing novel therapies for serious or life-threatening diseases with significant unmet needs. It leveraging Molecular Adhesion and Sealant Technology, platform, derived from over two decades of clinical, nonclinical, and manufacturing experience with purified and non-purified poloxamers to develop vepoloxamer, which also known as MST-188. The company was founded by Warren C. Lau in December 1995 and is headquartered in San Diego, CA. | - |
Richard Towne LeBuhn | M | 59 | 5 years | |
Michael West | M | 71 | 16 years | |
Joel Drescher | M | - |
University of California, Berkeley
| 5 years |
Nickhil Jakatdar | M | - |
University of California, Berkeley
| 4 years |
Jen L. Neumann | F | - |
University of California, Berkeley
| 4 years |
Bambang Susantono | M | 60 |
University of California, Berkeley
| 3 years |
Yi Ma | M | 51 |
University of California, Berkeley
| 4 years |
Chase Leavitt | M | 42 | 2 years | |
Kevin Cook | M | 53 | 1 years | |
Peter Greenleaf | M | 54 |
Mast Therapeutics, Inc.
![]() Mast Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Mast Therapeutics, Inc. is a biopharmaceutical company, which engages in developing novel therapies for serious or life-threatening diseases with significant unmet needs. It leveraging Molecular Adhesion and Sealant Technology, platform, derived from over two decades of clinical, nonclinical, and manufacturing experience with purified and non-purified poloxamers to develop vepoloxamer, which also known as MST-188. The company was founded by Warren C. Lau in December 1995 and is headquartered in San Diego, CA. | - |
Daniel K. Nomura | M | - |
University of California, Berkeley
| 9 years |
Laura Parada | M | - |
University of California, Berkeley
| 5 years |
Ki-Ha Lee | M | - |
University of California, Berkeley
| 5 years |
Howard I. Scher | M | 72 | 3 years | |
Cavan Redmond | M | 63 | 1 years | |
Andy Arno | M | 64 | 5 years | |
Nat Ricciardi | M | 75 | 5 years | |
Howard C. Dittrich | M | 71 |
Mast Therapeutics, Inc.
![]() Mast Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Mast Therapeutics, Inc. is a biopharmaceutical company, which engages in developing novel therapies for serious or life-threatening diseases with significant unmet needs. It leveraging Molecular Adhesion and Sealant Technology, platform, derived from over two decades of clinical, nonclinical, and manufacturing experience with purified and non-purified poloxamers to develop vepoloxamer, which also known as MST-188. The company was founded by Warren C. Lau in December 1995 and is headquartered in San Diego, CA. | 3 years |
David Ramsay | M | 59 |
Mast Therapeutics, Inc.
![]() Mast Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Mast Therapeutics, Inc. is a biopharmaceutical company, which engages in developing novel therapies for serious or life-threatening diseases with significant unmet needs. It leveraging Molecular Adhesion and Sealant Technology, platform, derived from over two decades of clinical, nonclinical, and manufacturing experience with purified and non-purified poloxamers to develop vepoloxamer, which also known as MST-188. The company was founded by Warren C. Lau in December 1995 and is headquartered in San Diego, CA. | 6 years |
Russell Skibsted | M | 65 | 4 years | |
Ted Love | M | 65 |
Mast Therapeutics, Inc.
![]() Mast Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Mast Therapeutics, Inc. is a biopharmaceutical company, which engages in developing novel therapies for serious or life-threatening diseases with significant unmet needs. It leveraging Molecular Adhesion and Sealant Technology, platform, derived from over two decades of clinical, nonclinical, and manufacturing experience with purified and non-purified poloxamers to develop vepoloxamer, which also known as MST-188. The company was founded by Warren C. Lau in December 1995 and is headquartered in San Diego, CA. | 1 years |
Stephen Farrell | M | 59 | 7 years | |
Gregory P. Hanson | M | 77 |
Mast Therapeutics, Inc.
![]() Mast Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Mast Therapeutics, Inc. is a biopharmaceutical company, which engages in developing novel therapies for serious or life-threatening diseases with significant unmet needs. It leveraging Molecular Adhesion and Sealant Technology, platform, derived from over two decades of clinical, nonclinical, and manufacturing experience with purified and non-purified poloxamers to develop vepoloxamer, which also known as MST-188. The company was founded by Warren C. Lau in December 1995 and is headquartered in San Diego, CA. | 2 years |
Jack Lief | M | 78 |
Mast Therapeutics, Inc.
![]() Mast Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Mast Therapeutics, Inc. is a biopharmaceutical company, which engages in developing novel therapies for serious or life-threatening diseases with significant unmet needs. It leveraging Molecular Adhesion and Sealant Technology, platform, derived from over two decades of clinical, nonclinical, and manufacturing experience with purified and non-purified poloxamers to develop vepoloxamer, which also known as MST-188. The company was founded by Warren C. Lau in December 1995 and is headquartered in San Diego, CA. | 9 years |
Carrie E. Carlander McQueen | F | 53 |
Mast Therapeutics, Inc.
![]() Mast Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Mast Therapeutics, Inc. is a biopharmaceutical company, which engages in developing novel therapies for serious or life-threatening diseases with significant unmet needs. It leveraging Molecular Adhesion and Sealant Technology, platform, derived from over two decades of clinical, nonclinical, and manufacturing experience with purified and non-purified poloxamers to develop vepoloxamer, which also known as MST-188. The company was founded by Warren C. Lau in December 1995 and is headquartered in San Diego, CA. | - |
Eric Rowinsky | M | 67 |
Mast Therapeutics, Inc.
![]() Mast Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Mast Therapeutics, Inc. is a biopharmaceutical company, which engages in developing novel therapies for serious or life-threatening diseases with significant unmet needs. It leveraging Molecular Adhesion and Sealant Technology, platform, derived from over two decades of clinical, nonclinical, and manufacturing experience with purified and non-purified poloxamers to develop vepoloxamer, which also known as MST-188. The company was founded by Warren C. Lau in December 1995 and is headquartered in San Diego, CA. | - |
Lewis J. Shuster | M | 68 |
Mast Therapeutics, Inc.
![]() Mast Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Mast Therapeutics, Inc. is a biopharmaceutical company, which engages in developing novel therapies for serious or life-threatening diseases with significant unmet needs. It leveraging Molecular Adhesion and Sealant Technology, platform, derived from over two decades of clinical, nonclinical, and manufacturing experience with purified and non-purified poloxamers to develop vepoloxamer, which also known as MST-188. The company was founded by Warren C. Lau in December 1995 and is headquartered in San Diego, CA. | 5 years |
Michael Surowiecki | M | - |
University of California, Berkeley
| 2 years |
Ron Roe | M | 47 |
University of California, Berkeley
| 4 years |
Jonathan Bradley Feske | M | - |
University of California, Berkeley
| 4 years |
Wai Wen | M | - |
University of California, Berkeley
| 4 years |
Hui Zhang | M | 52 |
University of California, Berkeley
| 3 years |
Tak Wai Wong | M | 47 |
University of California, Berkeley
| 4 years |
Lorna L. Tanner | F | - |
University of California, Berkeley
| 4 years |
Esina Alic | F | - |
University of California, Berkeley
| 2 years |
Kristine Diamond | F | 56 |
University of California, Berkeley
| 2 years |
Daniel Fetters | M | 50 |
University of California, Berkeley
| 4 years |
Irena Blind | F | - |
University of California, Berkeley
| 4 years |
Ann Bordetsky | F | - |
University of California, Berkeley
| 4 years |
Stan Miroshnik | M | - |
University of California, Berkeley
| 4 years |
Albert Wang | M | - |
University of California, Berkeley
| 4 years |
Abu Ramin | M | - |
University of California, Berkeley
| 4 years |
Gabe Turner | M | 42 |
University of California, Berkeley
| 4 years |
Mike Boggs | M | - |
University of California, Berkeley
| 4 years |
Brian D. Martin | M | - |
University of California, Berkeley
| 4 years |
Amit Mehrotra | M | - |
University of California, Berkeley
| 3 years |
Nathan Brostrom | M | - |
University of California, Berkeley
| 12 years |
B. C. Brant | M | - |
University of California, Berkeley
| 1 years |
Vitaly Bezrodnykh | M | - |
University of California, Berkeley
| 2 years |
Jeremy P. Kath | M | - |
University of California, Berkeley
| 2 years |
Jonathan Mi | M | - |
University of California, Berkeley
| 4 years |
Jay Traeger | M | - |
University of California, Berkeley
| 4 years |
Julie Liu | F | - |
University of California, Berkeley
| 2 years |
Linda Contreras | F | - |
University of California, Berkeley
| 4 years |
Karen Madden | F | - |
University of California, Berkeley
| 2 years |
Todd Ammons | M | - |
University of California, Berkeley
| 4 years |
Carol Tecla Christ | M | 79 |
University of California, Berkeley
| 6 years |
Adrienne Hudspeth | F | - |
University of California, Berkeley
| 4 years |
Jon David McAuliffe | M | - |
University of California, Berkeley
| 5 years |
Dominic Ang | M | 46 |
University of California, Berkeley
| 4 years |
Kanyu Cao | M | - |
University of California, Berkeley
| 3 years |
Ken M. Wisdom | M | - |
University of California, Berkeley
| 2 years |
Chris J. McBee | M | - |
University of California, Berkeley
| 2 years |
Yi Shan Li | M | 59 |
University of California, Berkeley
| 2 years |
Peter Smith | M | - |
University of California, Berkeley
| 3 years |
Timothy Kutzkey | M | 49 |
University of California, Berkeley
| 6 years |
Jon S. Orban | M | 55 |
University of California, Berkeley
| 4 years |
Paras P. Maniar | M | - |
University of California, Berkeley
| 4 years |
Seth D. Greenstein | M | - |
University of California, Berkeley
| 5 years |
Marcos Stefan Kulka Kuperman | M | - |
University of California, Berkeley
| 2 years |
Margo Diamond | M | - |
University of California, Berkeley
| 4 years |
Statistics
Country | Connections | % of total |
---|---|---|
United States | 100 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Brian Culley
- Personal Network